Duragesic-75

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

33 API Suppliers, 10 USDMF, 9 CEP/COS, 3 JDMF, 1 EU WC, 4 KDMF, 13 NDC API, 12 Listed Suppliers

DEVELOPMENTS

70 Drugs in Development

70 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

539 FDF Dossiers, 71 FDA Orange Book, 361 Europe, 16 Canada, 45 Australia, 19 South Africa, 27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Boai NKY Pharmaceuticals Ltd, 1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Alcedo Pharmachem, 5 BASF, 1 Huzhou Sunflower Pharmaceutical, 1 Microlex e.U, 1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

6 Fillers, Diluents & Binders, 5 Topical, 5 Direct Compression, 3 Film Formers & Plasticizers, 2 Granulation, 2 Solubilizers, 1 Controlled & Modified Release, 1 Taste Masking, 1 Coating Systems & Additives

DIGITAL CONTENT

220 News #PharmaBuzz

220 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 209 Regulatory FDF Prices, 14 Annual Reports

MARKET PLACE

5 APIs, 21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 6 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 11 Others

Xls

Filters

Duragesic-75

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Looking for Duragesic-75? Find Rheology Modifiers used in Duragesic-75 to address drug delivery challenges on PharmaCompass.

Duragesic-75

ACCESS ALL DATA

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

33 API Suppliers

10 USDMF

9 CEP/COS

3 JDMF

1 EU WC

4 KDMF

13 NDC API

12 Listed Suppliers

DEVELOPMENTS

70 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

539 FDF Dossiers

71 FDA Orange Book

361 Europe

16 Canada

45 Australia

19 South Africa

27 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

2 Boai NKY Pharmaceuticals Ltd

1 Nanjing Well Pharmaceutical

1 Actylis

1 Alcedo Pharmachem

5 BASF

1 Huzhou Sunflower Pharmaceutical

1 Microlex e.U

1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

6 Fillers, Diluents & Binders

5 Topical

5 Direct Compression

3 Film Formers & Plasticizers

2 Granulation

2 Solubilizers

1 Controlled & Modified Release

1 Taste Masking

1 Coating Systems & Additives

DIGITAL CONTENT

220 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions

209 Regulatory FDF Prices

14 Annual Reports

MARKET PLACE

5 APIs

21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents

6 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM

11 Others

Filters

Duragesic-75

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons